Browsing Tag
Ovarian Cancer
32 posts
Ernexa Therapeutics (NASDAQ: ERNA) surges 68% after Cellipont deal to advance ovarian cancer cell therapy ERNA‑101
Ernexa Therapeutics stock jumps 68% after partnering with Cellipont to manufacture its ovarian cancer cell therapy ERNA-101. Learn what’s driving investor interest.
Half of platinum-resistant ovarian cancer patients respond to Raludotatug deruxtecan in REJOICE-Ovarian01 trial
Find out how Raludotatug deruxtecan achieved a 50 % response rate in platinum-resistant ovarian cancer and what it means for future ADC therapies.
Merck’s KEYNOTE-B96 trial signals survival benefit in platinum-resistant ovarian cancer, but MRK stock dips
Merck's KEYNOTE-B96 trial shows survival benefit in ovarian cancer. See what it means for patients, pipeline, and MRK stock. Read full analysis now.
AbbVie’s bold gamble: Can Elahere really launch in the UK at full U.S. list price?
AbbVie plans to launch ovarian cancer drug Elahere in UK at U.S. price—testing NICE, NHS, and investor confidence in oncology pricing norms.
BCAL Diagnostics (ASX: BDX) shares rise after ClearNote deal — is this the turning point investors were waiting for?
BCAL Diagnostics (ASX: BDX) expands with ClearNote Health deal for ovarian and pancreatic cancer tests—can this pivot revive its struggling stock?
Verastem Oncology’s avutometinib plus defactinib trial in LGSOC published in JCO with robust clinical responses
Verastem Oncology published pivotal Phase 2 RAMP 201 trial results in JCO, showing strong response rates for avutometinib plus defactinib in recurrent LGSOC.
NeoGenomics launches PanTracer Tissue and HRD-enhanced profiling to accelerate ovarian cancer treatment decisions
NeoGenomics launches PanTracer Tissue and PanTracer Tissue + HRD to fast-track ovarian cancer treatment with next-gen genomic profiling and rapid HRD testing.
Cleo Diagnostics (ASX:COV) gains PLCO biobank access to strengthen FDA submission for ovarian cancer test
Cleo Diagnostics secures PLCO biobank access to enhance its ovarian cancer test FDA filing. Find out how this milestone strengthens global regulatory strategy.
AbbVie’s ELAHERE demonstrates 32% reduction in death risk for ovarian cancer patients
A final analysis of the Phase 3 MIRASOL trial has confirmed that ELAHERE (mirvetuximab soravtansine-gynx) provides a significant…
New data from Incyte highlights efficacy of CDK2 inhibitor in ovarian cancer; Pivotal trials expected in 2025
Incyte has announced new early-stage clinical data for INCB123667, a highly selective and potential first-in-class CDK2 inhibitor, showing…